FIELD: organic chemistry, pharmacy, pharmacy.
SUBSTANCE: invention relates to novel compounds designated for delivery of active substances to tissues of the following formula: 
wherein values of radicals R1-R7 are determined in claim 1 of the invention claim, and to their pharmaceutically acceptable salts. Also, invention relates to compositions designated for delivery of active substances to tissues and containing: (A) active substance and (B) at least one compound designated for delivery of active substance to animal tissues of the formula: 
wherein values of radicals R1-R7 are determined in claims 3-5 of the invention claim. Also, proposed invention relates to a standard medicinal formulation designated for delivery of active substances to body tissues and to a method for preparing indicated compositions and administration of substances for their delivery to body tissues.
EFFECT: valuable properties of compounds.
23 cl, 11 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF HIV INTEGRASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2002 |
|
RU2284315C2 |
| COMPOUNDS AND FORMULATIONS FOR ACTIVE SUBSTANCE DELIVERY | 2005 |
|
RU2530889C2 |
| COMPOSITIONS AND MIXTURES FOR DELIVERY OF ACTIVE AGENTS | 2005 |
|
RU2403237C2 |
| METHOD OF PRODUCING ALKYL-SUBSTITUTED 2-OXO-1,2-DIHYDROPYRIDINE-3,4-DICARBONITRILES | 2015 |
|
RU2577526C1 |
| QUATERNARY AMMONIUM SALTS BASED ON DERIVATIVES OF VITAMIN B6 | 2015 |
|
RU2607522C1 |
| ARYLMETHOXY ISOINDOLIN DERIVATIVE, COMPOSITIONS INCLUDING THEREOF AND METHODS OF THEIR APPLICATION | 2011 |
|
RU2567753C2 |
| AZO-DERIVATIVES OF AMINOPHENOLS, CAPABLE OF INHIBITING FORMATION OF ADVANCED GLYCATION END PRODUCTS | 2024 |
|
RU2839138C1 |
| QUATERNARY AMMONIUM COMPOUNDS BASED ON PENTAERYTHRITOL AND PYRIDOXINE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | 2023 |
|
RU2811203C1 |
| HYDROXAMIC ACIDS CONTAINING 1,2,4- AND 1,3,4-OXADIAZOLE NUCLEI AS POTENTIATORS OF ANTIBIOTIC ACTION | 2023 |
|
RU2830361C1 |
| LIGANDS, TROPIC TO PROSTATIC SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF FOR OBTAINING DOUBLE CONJUGATES WITH THERAPEUTIC AGENTS BASED THEREON FOR COMBINED THERAPY OF PSMA EXPRESSING TUMOURS | 2023 |
|
RU2841078C1 |
